These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 23092636

  • 1. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K, Basaria S.
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
    Crawford ED, Moul JW.
    Oncology (Williston Park); 2015 Jan; 29(1):55-8, 65-6. PubMed ID: 25592210
    [Abstract] [Full Text] [Related]

  • 10. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS.
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
    Walker LM, Tran S, Robinson JW.
    Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, Urologic Diseases in America Project.
    Cancer; 2007 Oct 01; 110(7):1493-500. PubMed ID: 17657815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.